ライフサイエンスコーパス: hepatitis B

1 cal development for the treatment of chronic hepatitis B.

2 country with an intermediate endemicity for hepatitis B.

3 a comeback, potentially increasing risk for hepatitis B.

4 rials aiming at a functional cure of chronic hepatitis B.

5 lerating the discovery of a cure for chronic hepatitis B.

6 the natural history and treatment of chronic hepatitis B.

7 strategy for the functional cure of chronic hepatitis B.

8 Four individuals were diagnosed with hepatitis B; 0 were diagnosed with HIV.

9 liver disease (58.0%), hepatitis C (26.0%), hepatitis B (10.0%), and alcohol (6.0%).

10 including for tuberculosis (91.6% screened), hepatitis B (95.8% screened), and human immunodeficiency

11 xposure among 128,861 patients with HIV-1 or hepatitis B (adjusted hazard ratio for NRTI exposure, 0.

12 prognosis in severe acute flares of chronic hepatitis B (AFOCHB) is often unclear.

13 In part 1, healthy adults without hepatitis B aged 18-65 years at one clinical research ce

14 As a control, 38 patients with acute hepatitis B (AHB) without liver failure were included.

15 e treatment exists for patients with chronic hepatitis B, although treatment is generally anticipated

16 therapeutic development for diseases such as hepatitis B and C and studying the natural history of ma

17 acilitate the planning and evaluation of the hepatitis B and C control program in Malaysia.

18 As the country moves toward hepatitis B and C elimination, population-based estimate

19 es are necessary to understand the burden of hepatitis B and C for evidence-based policy-making.

20 reat other viral infections, such as chronic hepatitis B and C in humans.

21 his study aims to estimate the prevalence of hepatitis B and C in Malaysia.

22 All blood samples were tested for hepatitis B and C markers including hepatitis B surface

23 Chronic hepatitis B and C viral infections are major risk factor

24 inery regulates host innate immunity against hepatitis B and C viral infections by inducing m(6)A mod

25 Hepatitis B and C virus infection in HCC were continuous

26 Hepatitis B and C virus-associated HCC became less commo

27 her chronic infections such as tuberculosis, hepatitis B and C, and HIV, as well as in autoimmunity a

28 study, including patients with cirrhosis and hepatitis B and C, from 2015 to 2017 who underwent treat

29 ne-third of the patients had been tested for hepatitis B and C.

30 y and pathogenesis in the setting of chronic hepatitis B and C.

31 omes in a nationwide cohort of patients with hepatitis B and D co-infection, cared for at secondary c

32 tent cells that supported the replication of hepatitis B and delta viruses.

33 There are now effective treatments for hepatitis B and hepatitis C, and follow-up after effecti

34 oholism or substance abuse history, 6.4% had hepatitis B and/or C, and 1.1% had significant fibrosis

35 ates of screening coverage for tuberculosis, hepatitis B, and HIV during the domestic medical examina

36 ir measurement during the natural history of hepatitis B, and on treatment with current and new agent

37 ir measurement during the natural history of hepatitis B, and on treatment with current and new agent

38 ficates, approximately 1800 persons die from hepatitis B annually in the United States; however, this

39 segmental glomerulosclerosis (FSGS), LN and hepatitis B associated glomerulonephritis (HBV-GN) signi

40 Reaching 90% hepatitis B birth dose coverage across all GBD regions w

41 Hepatitis B birth dose coverage of 90% is unlikely to be

42 st-effective strategy to achieve the WHO 90% hepatitis B birth dose coverage target in GBD regions an

43 human seroprotection, potentially useful for hepatitis B birth dose vaccination in resource-constrain

44 ible intermediates on the assembly path from hepatitis B capsid protein dimers to the 120-dimer capsi

45 Hepatitis B causes more than 800 000 deaths globally eac

46 Chronic hepatitis B (CHB) and nonalcoholic fatty liver disease a

47 ed gene transcripts in patients with chronic hepatitis B (CHB) in the absence of liver cirrhosis.

48 Chronic hepatitis B (CHB) infection functional cure is defined a

49 but overall population prevalence of chronic hepatitis B (CHB) infection remains high.

50 Chronic hepatitis B (CHB) is a significant global health concern

51 Chronic hepatitis B (CHB) is associated with a dysfunctional imm

52 Antiviral therapy for chronic hepatitis B (CHB) is effective and can substantially red

53 lthy donors exposed to IFN-alpha and chronic hepatitis B (CHB) patients starting IFN-alpha therapy.

54 loping liver cancer and cirrhosis in chronic hepatitis B (CHB) patients.

55 ce antigen (HBsAg) turnover rates in chronic hepatitis B (CHB) patients.

56 ctronic health record (EHR) alert on chronic hepatitis B (CHB) screening among at-risk Asian and Paci

57 rapeutic target for the treatment of chronic hepatitis B (CHB), but it is challenging to study this i

58 ay underestimate true mortality from chronic hepatitis B (CHB).

59 and worse immunological stage at ART start, hepatitis B coinfection, and residing in Thailand (all P

60 d poliomyelitis-Haemophilus influenza type b-hepatitis B combination vaccine were given at 2, 3, and

61 ere we investigate the conjugation of tandem Hepatitis B core (tHBcAg) VLPs and the model antigen GFP

62 3 tests-hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) total immunoglobuli

63 ng hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody (anti-HBc), antibodies against

64 elated antigen (qHBcrAg) and quantified anti-hepatitis B core antibody (qAnti-HBc) during tenofovir (

65 epatitis B surface antigen and antibodies to hepatitis B core antigen (anti-HBc) in HBsAg-negative pa

66 ation from an donor positive for antibody to hepatitis B core antigen (anti-HBc).

67 prevalence of HBV infection) and antibody to hepatitis B core antigen (anti-HBc; prevalence of HBV ex

68 e ability of hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) as surrogates

69 y was to describe the kinetics of quantified hepatitis B core-related antigen (qHBcrAg) and quantifie

70 Chronic hepatitis B develops more frequently in countries with h

71 NA) therapy; cohort B: 23 antibodies against hepatitis B e antigen (anti-HBe)-positive patients who s

72 reatment and assess their ability to predict hepatitis B e antigen (HBeAg) seroclearance in patients

73 Three cohorts of hepatitis B e antigen (HBeAg)-negative patients were stu

74 Hepatitis B e antigen (HBeAg)-positive adults with HBV D

75 The circulating hepatitis B e antigen (HBeAg, p17) is known to manipulat

76 ed with HBV in vitro, causing a reduction of hepatitis B e antigen and specific loss of cells express

77 ltivariable analysis adjusting for age, sex, hepatitis B e antigen serostatus, and diabetes, the pres

78 patitis A-E serology was measured, including hepatitis B e antigen, antibodies to hepatitis B e antig

79 cluding hepatitis B e antigen, antibodies to hepatitis B e antigen, antibodies to hepatitis D, hepati

80 In the subgroup of hepatitis B e antigen-negative patients with HBV DNA lev

81 utions in liver biopsy specimens of two anti-hepatitis B e antigen-positive (HBe(+)) chronic HBV (CHB

82 chronic HBV infection who were negative for hepatitis B e antigen.

83 26.8% (95% CI, 22.0%-31.9%) was positive to hepatitis B e antigen.

84 outcomes, such as virologic suppression and hepatitis B e-antigen (HBeAg) or hepatitis B surface ant

85 CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive.

86 tion strategies are essential to achieve the hepatitis B elimination goal.

87 nisation for diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Streptococcu

88 The e antigen of hepatitis B (HBeAg) is positively associated with an inc

89 Hepatitis B (HBV) and fatty liver disease (FLD) are comm

90 f childbearing age in the US, but changes in hepatitis B (HBV) infection have not been studied.

91 med to investigate the long-term outcomes in hepatitis B (HBV)/hepatitis C virus (HCV) dual-infected

92 d for treating viral infections such as HIV, hepatitis B, hepatitis C, influenza, and SARS-CoV-2.

93 uring the exam, including tuberculosis (TB), hepatitis B, hepatitis C, malaria, strongyloidiasis, sch

94 ty and safety of a 3-antigen (S/preS1/preS2) hepatitis B (HepB) vaccine (3AV), to a single antigen va

95 rhosis (HR for NHW 1.35; 95% CI, 1.19-1.52), hepatitis B (HR for NHW 1.35; 95% CI, 0.98-1.87), hepati

96 Universal hepatitis B immunisation at birth and in infancy is the

97 r enzymes may facilitate the cure of chronic hepatitis B.IMPORTANCE Persistent HBV infection relies o

98 that can induce a functional cure of chronic hepatitis B in a small, but significant, fraction of tre

99 odels of human leukemia, prostate cancer and hepatitis B-induced hepatocellular carcinoma, repeated i

100 serum were elevated in patients with chronic hepatitis B infection (CHB) and acute-on-chronic liver f

101 Hepatitis B infection is a significant worldwide health

102 gent entecavir was commenced for his chronic hepatitis B infection.

103 genetic barrier for the treatment of chronic hepatitis B infection.

104 rs (NRTI), drugs approved to treat HIV-1 and hepatitis B infections, also block inflammasome activati

105 Chronic hepatitis B is caused by prolonged infection with the he

106 ffer cells, which are not natural targets of hepatitis B, leads to differentiation of CD8(+) T cells

107 .IMPORTANCE A curative treatment for chronic hepatitis B must eliminate the virus from the liver, but

108 Patients with known CNS lymphoma, active hepatitis B or C infection, or HIV were excluded.

109 ng cholangitis, primary biliary cholangitis, hepatitis B or C virus infection, autoimmune hepatitis,

110 biliary cholangitis, chronic infection with hepatitis B or C virus, autoimmune hepatitis, or alcohol

111 l adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and wh

112 ointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.

113 with men, 55.2% and 75.1% among persons with hepatitis B or hepatitis C, and 22.6% and 25.9% among th

114 T cells from healthy donors and from chronic hepatitis B patients became polyfunctional effector cell

115 ntration ranging from 0.1 to 60 ng/mL) of 10 hepatitis B patients, showing consistent results with cl

116 chemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (D

117 Older age and hepatitis B positivity predicted liver injury.

118 8(+) T cells to hepatotropic viruses such as hepatitis B range from dysfunction to differentiation in

119 four in the intravenous group (sepsis [n=2], hepatitis B reactivation [n=1], and Pneumocystis jirovec

120 for a median of 3 years (ancillary study of Hepatitis B Research Network).

121 sites in the United States and Canada of the Hepatitis B Research Network.

122 We evaluated immunogenicity based on hepatitis B surface (HBs) antibody titers at Days 1, 28,

123 Hepatitis B surface antibody (anti-HBs) <10 IU/mL in HBV

124 revalence and trends in protective levels of hepatitis B surface antibody (anti-HBs) from 2003 to 201

125 Levels of antibody to hepatitis B surface antigen (HBsAg) (anti-HBs) and HBsAg

126 All were positive for hepatitis B surface antigen (HBsAg) and HBeAg and had hi

127 mous separation of hepatitis B viral DNA and hepatitis B surface antigen (HBsAg) concentrations occur

128 Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and

129 Antibody-mediated clearance of hepatitis B surface antigen (HBsAg) from the circulation

130 Secondary outcomes were reductions in hepatitis B surface antigen (HBsAg) in control and exper

131 achieving either anti-HBs seroconversion or hepatitis B surface antigen (HBsAg) loss.

132 ALT) >=2-fold the upper limit of normal, and hepatitis B surface antigen (HBsAg) seroclearance.

133 API patients who had not yet completed hepatitis B surface antigen (HBsAg) testing were identif

134 , heavy water labeling was used to determine hepatitis B surface antigen (HBsAg) turnover rates in ch

135 All women with reactive samples for hepatitis B surface antigen (HBsAg) were assessed with a

136 sted for hepatitis B and C markers including hepatitis B surface antigen (HBsAg), anti-hepatitis B co

137 therapy should be tested for HBV by 3 tests-hepatitis B surface antigen (HBsAg), hepatitis B core an

138 collected data from 2666 adults positive for hepatitis B surface antigen (HBsAg), infected with HBV g

139 hepatitis D, hepatitis B virus (HBV) DNA for hepatitis B surface antigen (HBsAg)-positive participant

140 vent hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-positive patients re

141 s of adults that reported prevalence of both hepatitis B surface antigen (HBsAg; prevalence of HBV in

142 5% (12/225) of them had positive hepatitis B surface antigen and 13.4% had past infection

143 Ag)-positive participants, and antibodies to hepatitis B surface antigen and antibodies to hepatitis

144 n of 4.6 years, the cumulative incidences of hepatitis B surface antigen and HBeAg seroclearance were

145 ression and hepatitis B e-antigen (HBeAg) or hepatitis B surface antigen loss or seroconversion; the

146 Participants in Cohort B without detectable hepatitis B surface antigen were assigned by blocked ran

147 cohorts B1 and B2, and those with detectable hepatitis B surface antigen were assigned to cohort B3.

148 HBV infection (hepatitis B surface antigen) was diagnosed with serologi

149 enced HBV functional cure (confirmed loss of hepatitis B surface antigen).

150 oteins of three sizes, collectively known as hepatitis B surface antigen, and adopts multiple conform

151 immunoglobulin (Ig) or IgG, and antibody to hepatitis B surface antigen-but anticancer therapy shoul

152 Participants were anti-HIV/hepatitis B surface antigen-positive adults from eight c

153 o multivariate analysis were the etiology of hepatitis B, the stage of Barcelona Clinic Liver Cancer

154 is mathematical modelling study of perinatal hepatitis B transmission and disease progression, we est

155 This study compares self-reported hepatitis B vaccination and screening between US-born an

156 ign-born women of reproductive age had lower hepatitis B vaccination and screening coverage than US-b

157 ame region; 18.8% more children received the hepatitis B vaccine birth dose and the hepatitis B virus

158 Alum-adjuvanted hepatitis B vaccine elicited vital signs and inflammator

159 cularly promising for birth dose delivery of hepatitis B vaccine in resource-constrained regions.

160 olvable microneedle patch (dMNP) delivery of hepatitis B vaccine in rhesus macaques and provides evid

161 A hepatitis B vaccine was administered to 66 young Latvian

162 he highest levels of antibody titers against hepatitis B vaccine.

163 ctiveness of implementing ambient storage of hepatitis B vaccines under a controlled temperature chai

164 A dichotomous separation of hepatitis B viral DNA and hepatitis B surface antigen (H

165 lele, a gain-of-function variant, with human hepatitis B viral persistence.

166 We have previously reported that hepatitis B viral RNAs are m(6)A-modified, displaying a

167 pe similarity driving immune response in the hepatitis B virally infected liver cancer TCGA cohort, a

168 New hepatitis B virions released from infected hepatocytes a

169 osis and other chronic liver diseases due to hepatitis B virus (12.2 million) and hepatitis C virus (

170 C virus (10.4 million), liver cancer due to hepatitis B virus (9.4 million), rheumatic heart disease

171 Hepatitis B virus (HBV) and hepatitis C virus (HCV) caus

172 Hepatitis B virus (HBV) and hepatitis C virus (HCV) rema

173 er extensive mixed tailing in transcripts of hepatitis B virus (HBV) and human cytomegalovirus (HCMV)

174 ed viruses such as Epstein-Barr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV;

175 Patients co-infected with hepatitis B virus (HBV) and the human immunodeficiency v

176 the details of assembly/release pathways of hepatitis B virus (HBV) are still unknown.

177 Hepatitis B virus (HBV) can transmit through needle shar

178 enchmarked by monitoring the assembly of the hepatitis B virus (HBV) capsid.

179 Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenof

180 HCV) with direct-acting antivirals (DAAs) in hepatitis B virus (HBV) coinfection can result in HBV re

181 characteristics and comorbidities to chronic hepatitis B virus (HBV) controls using propensity scores

182 tion efforts, their lack of activity against hepatitis B virus (HBV) could limit their global impact,

183 Hepatitis B virus (HBV) covalently closed circular (ccc)

184 The biosynthesis of hepatitis B virus (HBV) covalently closed circular DNA (

185 itis B e antigen, antibodies to hepatitis D, hepatitis B virus (HBV) DNA for hepatitis B surface anti

186 The paucity of hepatitis B virus (HBV) DNA measurement in low-/middle-i

187 We examined factors associated with hepatitis B virus (HBV) exposure among people who report

188 r DNA (cccDNA) is the persistent form of the hepatitis B virus (HBV) genome in viral infection and an

189 o date, conflicting data exist as to whether hepatitis B virus (HBV) has the ability to induce innate

190 screened 693 European and African shrews for hepatitis B virus (HBV) homologs to elucidate the enigma

191 the basis for replication and persistence of hepatitis B virus (HBV) in the chronically infected live

192 e the establishment of a seronegative occult hepatitis B virus (HBV) infection (OBI) in a successfull

193 Hepatitis B virus (HBV) infection affects approximately

194 Rare individuals can naturally clear chronic hepatitis B virus (HBV) infection and acquire protection

195 Therapies for chronic hepatitis B virus (HBV) infection are urgently needed be

196 k Force (USPSTF) found antiviral therapy for hepatitis B virus (HBV) infection associated with improv

197 Antagonism of host immune defenses against hepatitis B virus (HBV) infection by the viral proteins

198 Hepatitis B virus (HBV) infection can be prevented throu

199 resistance to IFN therapy.IMPORTANCE Chronic hepatitis B virus (HBV) infection continues to be a majo

200 Screening for hepatitis B virus (HBV) infection during pregnancy ident

201 s conducted to estimate the global burden of hepatitis B virus (HBV) infection in people living with

202 Chronic hepatitis B virus (HBV) infection is a global public hea

203 Hepatitis B virus (HBV) infection is a major cause of ac

204 Chronic hepatitis B virus (HBV) infection is a major public heal

205 Chronic hepatitis B virus (HBV) infection is a risk factor for h

206 Hepatitis B virus (HBV) infection persists because the v

207 Acute hepatitis B virus (HBV) infection remains a frequent cau

208 Hepatitis B virus (HBV) infection remains a major global

209 Development Goals (SDGs) for elimination of hepatitis B virus (HBV) infection set ambitious targets

210 infection (LTBI), 63.5% were susceptible to hepatitis B virus (HBV) infection, and 31.0% had at leas

211 hough there is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies are protec

212 nt of a treatment regimen for curing chronic hepatitis B virus (HBV) infection.

213 ng the immune-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection.

214 Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections can lead to cirrhosis

215 ing age in the United States, but changes in hepatitis B virus (HBV) infections have not been studied

216 substantial increase in the number of acute hepatitis B virus (HBV) infections in the United States.

217 Chronic hepatitis B virus (HBV) infections result in 887,000 dea

218 Hepatitis B virus (HBV) integration has implications for

219 ra DNA (vh-DNA), generated from junctions of hepatitis B virus (HBV) integration in the HCC chromosom

220 Hepatitis B virus (HBV) is a leading cause of liver dise

221 Hepatitis B virus (HBV) is a leading cause of liver fail

222 iral and host proteins on HBV-DNA.IMPORTANCE Hepatitis B virus (HBV) is a major global health concern

223 Hepatitis B virus (HBV) is a major health problem worldw

224 Its occurrence as a satellite virus of hepatitis B virus (HBV) is a singular case in animal vir

225 Hepatitis B virus (HBV) is a unique, tiny, partially dou

226 Hepatitis B virus (HBV) is an important but difficult to

227 h, particularly in sub-Saharan Africa, where hepatitis B virus (HBV) is an important risk factor.

228 virus (HDV) superinfection in patients with hepatitis B virus (HBV) is associated with rapid progres

229 Hepatitis B virus (HBV) is the leading cause of hepatoce

230 Hepatitis B virus (HBV) is the major causative factor of

231 )ide analogue (NA) is recommended to prevent hepatitis B virus (HBV) reactivation in hepatitis B surf

232 esponse and Organ failure) for patients with Hepatitis B Virus (HBV) related acute-on-chronic liver f

233 Hepatitis B virus (HBV) remains a major global health pr

234 Despite an effective vaccine, hepatitis B virus (HBV) remains a major public health th

235 79), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated

236 plays a role in the epigenetic regulation of hepatitis B virus (HBV) replication.

237 We have evaluated the ability of hepatitis B virus (HBV) RNA and hepatitis B core-related

238 presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management.

239 ers (NAPs) inhibit assembly and secretion of hepatitis B virus (HBV) subviral particles.

240 PXL are more active against alphaviruses and hepatitis B virus (HBV) than ZAPS and ZAPM and elucidate

241 Smoking interacts with hepatitis B virus (HBV) to increase the risk of hepatoce

242 is a host restriction factor that suppresses hepatitis B virus (HBV) transcription.

243 Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalc

244 entified or confirmed clonal integrations of hepatitis B virus (HBV), human papillomavirus (HPV), Eps

245 -residing pathogens, Schistosoma mansoni and hepatitis B virus (HBV), is barely understood.

246 B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increas

247 to exclude and confirm advanced fibrosis in hepatitis B virus (HBV)-human immunodeficiency virus (HI

248 cellular carcinoma (HCC) is most striking in hepatitis B virus (HBV)-related cases.

249 the first proteogenomic characterization of hepatitis B virus (HBV)-related hepatocellular carcinoma

250 apeutic approaches to augment the endogenous hepatitis B virus (HBV)-specific T cell response in CHB

251 device for the quantitative detection of the hepatitis B virus (HBV)-the major cause of liver cirrhos

252 antiviral activity of AdrA was addressed in hepatitis B virus (HBV)-transgenic and adenovirus-associ

253 verse transcriptase (RT) activity of HIV and hepatitis B virus (HBV).

254 he US are living with chronic infection with hepatitis B virus (HBV).

255 incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfect

256 inovirus [n = 5], and parechovirus [n = 2]), hepatitis B virus (n = 10), cytomegalovirus (n = 9), Eps

257 Other positive viral detections included hepatitis B virus (n = 2), human pegivirus 1 (n = 2), Ep

258 ce antigen and 13.4% had past infection with hepatitis B virus (positive anti-HBcore).

259 sfusion-transmitted infectious agents (TTIs; hepatitis B virus [HBV], HIV, human T-cell lymphotropic

260 ly recruits adaptive responses as opposed to hepatitis B virus and cancer-testis antigens.

261 confirm upregulation of Gal-9 on T cells in hepatitis B virus and HPV infections.

262 ce the risk of environmental transmission of hepatitis B virus but also open up the possibility of te

263 It is likely that the closely related hepatitis B virus capsid protein undergoes similar struc

264 ed a prolonged suppression of human and duck hepatitis B virus cccDNA transcription, which is associa

265 ned (1:1) HLA-B*5701-negative adults without hepatitis B virus co-infection to receive coformulated b

266 those with a human immunodeficiency virus or hepatitis B virus coinfection, and those treated with bo

267 age, gender, smoking status, hepatitis C and hepatitis B virus coinfection, group of exposure, nadir

268 Serum qHBcrAg, qAnti-HBc, and hepatitis B virus DNA were obtained at TDF initiation an

269 gical response after hepatitis C, suppressed hepatitis B virus during treatment, and alcoholic and no

270 istinct methylation events in the integrated hepatitis B virus genome.

271 In Asia, HCCs from patients with hepatitis B virus have been efficiently converted into P

272 eterminants of the failed immune response to hepatitis B virus in patients with chronic infection.

273 y 247 million people are living with chronic hepatitis B virus infection (CHB), and the development o

274 d the hepatitis B vaccine birth dose and the hepatitis B virus infection rate was 4 times lower.

275 ypes and several disease outcomes, including hepatitis B virus infection(5-7), graft-versus-host dise

276 naive and HLA-B*5701 negative, did not have hepatitis B virus infection, and had an estimated glomer

277 sity control, immunizing populations against hepatitis B virus infection, and screening for colorecta

278 immune dysfunction in patients with chronic hepatitis B virus infection, immunotherapy strategies in

279 fic T-cell immunity in patients with chronic hepatitis B virus infection.

280 les with targeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to sp

281 arcinomas (HCCs) from patients infected with hepatitis B virus or adeno-associated virus type 2, due

282 of 3.3 x 10(8) particles/mL was obtained for hepatitis B virus T = 4 capsids with a 1.3 muL sample.

283 on coverage and greater lifetime exposure to hepatitis B virus than US-born women.

284 epatitis delta virus (HDV) is a satellite of hepatitis B virus that increases the severity of acute a

285 epatitis delta virus (HDV) is a satellite of hepatitis B virus that increases the severity of liver d

286 nation, girls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms.

287 d by therapeutic targeting of HBx.IMPORTANCE Hepatitis B virus X protein (HBx) is a promising drug ta

288 that can affect replication of retroviruses, hepatitis B virus, and hepatitis C virus (HCV).

289 retrotransposons, and other viruses such as hepatitis B virus, but can cause a mutator phenotype in

290 our understanding of the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liv

291 m to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of ma

292 Other STIs, except hepatitis B virus, were also more prevalent among HIV-in

293 g the study, age-standardized mortality from hepatitis B virus-related extrahepatic complications inc

294 with human immunodeficiency virus (HIV) and hepatitis B virus.

295 rus (WHV), a hepadnavirus closely related to hepatitis B virus.

296 la, influenza A, human immunodeficiency, and hepatitis B viruses are examined in the first section; t

297 nsion, type 2 diabetes mellitus, and chronic hepatitis B with cirrhosis presented with a 2-week histo

298 erapeutic option in the treatment of chronic hepatitis B, with our lead candidate now entering trials

299 The hepatitis B X protein (HBx) plays a role in the epigenet

300 Hepatitis B X protein transgenic mouse model of HCC reca